Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lifastuzumab vedotin
- Development stage
- Phase 2
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
Lifastuzumab vedotin is an experimental antibody-drug conjugate (ADC) developed for the treatment of cancer. It consists of a humanized monoclonal antibody targeting SLC34A2 (also known as sodium-dependent phosphate transport protein 2B or NaPi2b), which is highly expressed in certain tumors such as ovarian and lung cancers. The antibody is conjugated via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) linker to the cytotoxic payload monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization that disrupts mitosis and induces apoptosis in targeted cells. Lifastuzumab vedotin was primarily investigated for platinum-resistant ovarian cancer and non-small cell lung cancer but development was discontinued after phase II trials failed to meet primary endpoints[4][5][6].
- Other names
- Anti-NaPi2bAnti-NaPi-2bAnti-NaPi 2bNaPi2b-ADCNaPi-2b-ADCNaPi 2b-ADCNaPi3bNaPi-3bNaPi 3b
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)
Beyond the preview
Go deeper on lifastuzumab vedotin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lifastuzumab vedotin.